九安医疗(002432) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥762,296,613.07, a decrease of 49.03% compared to ¥1,495,439,073.13 in the same period last year[3] - Net profit attributable to shareholders was ¥247,428,846.59, down 58.86% from ¥601,496,251.76 year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥315,771,994.80, a decrease of 10.58% compared to ¥353,145,033.66 in the previous year[3] - The net cash flow from operating activities was ¥167,048,901.89, down 78.43% from ¥774,274,874.97 in the same period last year[3] - The company's basic earnings per share decreased to ¥0.5570, down 56.39% from ¥1.2772 in the same period last year[3] - The weighted average return on equity was 1.28%, down from 3.02% in the previous year, a decrease of 1.74%[3] - Total operating revenue for Q1 2024 was ¥762,296,613.07, a decrease of 49% compared to ¥1,495,439,073.13 in the same period last year[16] - The company reported a net profit of ¥175,801,806.06 for Q1 2024, compared to ¥119,787,222.87 in the previous year, marking an increase of approximately 46.8%[16] - The net profit for Q1 2024 was CNY 310,478,780.77, a decrease of 56.6% compared to CNY 715,140,634.14 in the same period last year[17] - The total comprehensive income of CNY 357,194,274.76, compared to CNY 454,029,305.09 in the previous year, reflecting a decline of 21.4%[17] - Earnings per share (EPS) for Q1 2024 were CNY 0.5570, down from CNY 1.2772 in Q1 2023, representing a decrease of 56.4%[17] Assets and Liabilities - The total assets at the end of the reporting period were ¥23,374,666,912.49, an increase of 3.34% from ¥22,619,116,790.11 at the end of the previous year[3] - Total liabilities rose to ¥3,958,833,216.51, up from ¥2,794,705,681.74, indicating an increase of approximately 42%[15] - The total equity attributable to shareholders decreased to ¥18,741,407,376.32 from ¥19,229,372,817.81, a decline of about 2.54%[15] - Cash and cash equivalents decreased to ¥1,871,977,553.68 from ¥2,461,263,082.11, a drop of approximately 24%[14] - The cash and cash equivalents at the end of the period were CNY 1,261,377,867.18, a decrease from CNY 5,527,897,584.36 at the end of the previous year[19] Investment and Financing Activities - Long-term borrowings increased significantly by 435.59% to ¥1,580,000,000.00, primarily due to new long-term loans obtained during the reporting period[6] - The company raised CNY 1,768,210,000.00 through borrowings during the financing activities[19] - The net cash outflow from investing activities was CNY 1,756,853,070.51, compared to a net outflow of CNY 732,707,257.50 in the same period last year[18] - The company recorded a total of CNY 3,451,931,913.14 in cash inflows from investing activities, an increase from CNY 3,305,853,178.30 year-over-year[18] - The company plans to establish a partnership with Tianjin Haitang Venture Capital Management Center, with a total investment scale of up to RMB 1.251 billion, and the first phase of investment is expected to be RMB 500.4 million[11] - The company intends to repurchase shares in the secondary market with a total amount not less than RMB 600 million and not exceeding RMB 1.2 billion, with a maximum repurchase price of RMB 45 per share[11] - The company will invest no more than RMB 356 million in the Tianjin Tiankai Ji'an Haihe Haitang Equity Investment Fund, which has a target fundraising scale of RMB 5 billion[11] - The company’s investment in the Tianjin Jiutong Venture Capital Partnership is part of a broader strategy to enhance its market position and shareholder value[11] Shareholder Information - The first quarter report indicates a significant change in the top 10 shareholders due to share lending activities[9] - The top 10 shareholders hold a total of 2.29% of the company's total share capital, with the largest shareholder holding 11,193,962 shares[10] - The company reported that the total number of shares held by shareholders with more than 5% ownership has changed due to share lending activities[9] - The total number of shares held by the top 10 unrestricted circulating shareholders is 2.22% of the total share capital[10] - The company has a plan to complete the capital contribution within four years, which will not significantly impact cash flow[11] - The company’s share repurchase is aimed at maintaining company value and shareholder rights[12] Operational Costs and Expenses - Total operating costs for Q1 2024 were ¥473,480,332.91, down from ¥785,986,402.06, reflecting a 40% reduction[16] - Research and development expenses decreased to ¥53,857,292.79 from ¥72,848,101.89, a reduction of approximately 26%[16] - The company's inventory decreased to ¥229,345,590.91 from ¥282,895,131.72, a reduction of about 19%[14]